VAMP8 facilitates cellular proliferation and temozolomide resistance in human glioma cells.

abstract：:Tobacco products are major contributors of exogenous N-nitroso compounds, a group of potent neurocarcinogens. Overall results from studies of smoking and brain tumors have been null, but have provided little information on duration, age at smoking initiation, and latency. We prospectively examined the relation between...

journal_title：Neuro-oncology

authors： Holick CN,Giovannucci EL,Rosner B,Stampfer MJ,Michaud DS

更新日期：2007-07-01 00:00:00

abstract：BACKGROUND:Available evidence on diet and glioma risk comes mainly from studies with retrospective collection of dietary data. To minimize possible differential dietary recall between those with and without glioma, we present findings from 3 large prospective studies. METHODS:Participants included 692 176 from the UK ...

journal_title：Neuro-oncology

authors： Kuan AS,Green J,Kitahara CM,De González AB,Key T,K Reeves G,Floud S,Balkwill A,Bradbury K,Liao LM,Freedman ND,Beral V,Sweetland S,Million Women Study, the NIH-AARP study, and the PLCO study.

更新日期：2019-07-11 00:00:00

abstract：BACKGROUND:Antiangiogenic therapy of vestibular schwannoma (VS) in type 2 neurofibromatosis can produce tumor shrinkage with response rates of 40%-60%. This study examines the predictive value of parameter-derived MRI in this setting. METHODS:Twelve patients with 20 VSs were recruited. Each had at least one rapidly gr...

journal_title：Neuro-oncology

authors： Li KL,Djoukhadar I,Zhu X,Zhao S,Lloyd S,McCabe M,McBain C,Evans DG,Jackson A

更新日期：2016-02-01 00:00:00

abstract：:Tumor treating fields (TTFields) are low-intensity electric fields alternating at an intermediate frequency (200kHz), which have been demonstrated to block cell division and interfere with organelle assembly. This novel treatment modality has shown promise in a variety of tumor types. It has been evaluated in randomiz...

journal_title：Neuro-oncology

authors： Hottinger AF,Pacheco P,Stupp R

更新日期：2016-10-01 00:00:00

abstract：BACKGROUND:Meningiomas are the most commonly diagnosed primary intracranial neoplasms. Despite significant advances in modern therapies, the management of malignant meningioma and skull base meningioma remains a challenge. Thus, the development of new treatment modalities is urgently needed for these difficult-to-treat...

journal_title：Neuro-oncology

authors： Iwami K,Natsume A,Ohno M,Ikeda H,Mineno J,Nukaya I,Okamoto S,Fujiwara H,Yasukawa M,Shiku H,Wakabayashi T

更新日期：2013-06-01 00:00:00

abstract：:Background Nuclear factor IA (NFIA), a transcription factor and essential regulator in embryonic glial development, is highly expressed in human glioblastoma (GBM) compared with normal brain, but its contribution to GBM and cancer pathogenesis is unknown. Here we demonstrate a novel role for NFIA in promoting growth a...

journal_title：Neuro-oncology

authors： Lee JS,Xiao J,Patel P,Schade J,Wang J,Deneen B,Erdreich-Epstein A,Song HR

更新日期：2014-01-01 00:00:00

abstract：:Death receptor targeting has emerged as one of the promising novel approaches of cancer therapy. The activation of one such prototypic death receptor, CD95 (Fas/APO-1), has remained controversial because CD95 agonistic molecules have exhibited either too strong toxicity or too little activity. The natural CD95 ligand ...

journal_title：Neuro-oncology

authors： Eisele G,Roth P,Hasenbach K,Aulwurm S,Wolpert F,Tabatabai G,Wick W,Weller M

更新日期：2011-02-01 00:00:00

abstract：BACKGROUND:RTOG 0625/ACRIN 6677 is a multicenter, randomized, phase II trial of bevacizumab with irinotecan or temozolomide in recurrent glioblastoma (GBM). This study investigated whether early posttreatment progression on FLAIR or postcontrast MRI assessed by central reading predicts overall survival (OS). METHODS:O...

journal_title：Neuro-oncology

authors： Boxerman JL,Zhang Z,Safriel Y,Larvie M,Snyder BS,Jain R,Chi TL,Sorensen AG,Gilbert MR,Barboriak DP

更新日期：2013-07-01 00:00:00

abstract：:As immunotherapy assumes a central role in the management of many cancers, ongoing work is directed at understanding whether immune-based treatments will be successful in patients with glioblastoma (GBM). Despite several large studies conducted in the last several years, there remain no FDA-approved immunotherapies in...

journal_title：Neuro-oncology

authors： Dunn GP,Cloughesy TF,Maus MV,Prins RM,Reardon DA,Sonabend AM

更新日期：2020-10-14 00:00:00

abstract：:Vestibular schwannomas (VS) arising sporadically or in patients with neurofibromatosis type 2 (NF2) consistently lack expression of Merlin, a tumor suppressor. Conventional treatment options include surgery and radiotherapy but there is no validated medical option. Recent evidence suggests that Merlin deficiency may r...

journal_title：Neuro-oncology

authors： Ammoun S,Cunliffe CH,Allen JC,Chiriboga L,Giancotti FG,Zagzag D,Hanemann CO,Karajannis MA

更新日期：2010-08-01 00:00:00

abstract：BACKGROUND:Diagnostic accuracy in previous studies of O-(2-[18F]-fluoroethyl)-L-tyrosine (18F-FET) PET in patients with suspected recurrent glioma may be influenced by prolonged dynamic PET acquisitions, heterogeneous populations, different non-standard-of-care therapies, and PET scans performed at different time point...

journal_title：Neuro-oncology

authors： Bashir A,Mathilde Jacobsen S,Mølby Henriksen O,Broholm H,Urup T,Grunnet K,Andrée Larsen V,Møller S,Skjøth-Rasmussen J,Skovgaard Poulsen H,Law I

更新日期：2019-12-17 00:00:00

abstract：BACKGROUND:More than 90% of patients with diffuse intrinsic pontine glioma (DIPG) will die within 2 years of diagnosis. Patients deteriorate rapidly during the disease course, which severely impairs their quality of life. To date, no specific research on this clinically important subject has been conducted. This study ...

journal_title：Neuro-oncology

authors： Veldhuijzen van Zanten SE,van Meerwijk CL,Jansen MH,Twisk JW,Anderson AK,Coombes L,Breen M,Hargrave OJ,Hemsley J,Craig F,Cruz O,Kaspers GJ,van Vuurden DG,Hargrave DR,SIOPE DIPG Network.

更新日期：2016-04-01 00:00:00

abstract：BACKGROUND:The objective was to evaluate the risk and predictors of developing leptomeningeal disease (LMD) in patients with brain metastases treated with 5-fraction hypofractionated stereotactic radiotherapy (HSRT). METHODS:Patients treated with HSRT for intact brain metastases and/or surgical cavities were reviewed ...

journal_title：Neuro-oncology

authors： Nguyen TK,Sahgal A,Detsky J,Atenafu EG,Myrehaug S,Tseng CL,Husain Z,Heyn C,Maralani P,Ruschin M,Perry J,Soliman H

更新日期：2020-01-11 00:00:00

abstract：Background:Depending on the level, differentiation state, and tumor stage, reactive nitrogen and oxygen species inhibit or increase cancer growth and tumor initiating cell maintenance. The rate-limiting enzyme in a pathway that can regulate reactive species production but has not been thoroughly investigated in gliobla...

journal_title：Neuro-oncology

authors： Tran AN,Walker K,Harrison DG,Chen W,Mobley J,Hocevar L,Hackney JR,Sedaka RS,Pollock JS,Goldberg MS,Hambardzumyan D,Cooper SJ,Gillespie Y,Hjelmeland AB

更新日期：2018-07-05 00:00:00

abstract：:The 2007 World Health Organization (WHO) classification of brain tumors did not use molecular abnormalities as diagnostic criteria. Studies have shown that genotyping allows a better prognostic classification of diffuse glioma with improved treatment selection. This has resulted in a major revision of the WHO classifi...

journal_title：Neuro-oncology

authors： van den Bent MJ,Weller M,Wen PY,Kros JM,Aldape K,Chang S

更新日期：2017-05-01 00:00:00

abstract：BACKGROUND:Anaplastic oligodendroglial tumors are rare, and median survival varies widely. Analysis of 1p19q deletion is performed commonly and is an important prognostic factor. However, age and other clinical variables also carry prognostic value, and it is unclear how to incorporate them into clinical decision makin...

journal_title：Neuro-oncology

authors： Panageas KS,Reiner AS,Iwamoto FM,Cloughesy TF,Aldape KD,Rivera AL,Eichler AF,Louis DN,Paleologos NA,Fisher BJ,Ashby LS,Cairncross JG,Urgoiti GB,Wen PY,Ligon KL,Schiff D,Robins HI,Rocque BG,Chamberlain MC,Mason WP,

更新日期：2014-11-01 00:00:00

abstract：:Glioblastoma (GBM) is the most common malignant primary brain tumor. Its incidence continues to increase in the elderly because the older segment of the population is growing faster than any other age group. Most clinical studies exclude elderly patients, and "standards of care" do not exist for GBM patients aged >70 ...

journal_title：Neuro-oncology

authors： Bauchet L,Zouaoui S,Darlix A,Menjot de Champfleur N,Ferreira E,Fabbro M,Kerr C,Taillandier L

更新日期：2014-11-01 00:00:00

abstract：:The individualized care of glioma patients ought to benefit from imaging biomarkers as precocious predictors of therapeutic efficacy. Contrast enhanced MRI and [(18)F]-fluorodeoxyglucose (FDG)-PET are routinely used in clinical settings; their ability to forecast the therapeutic response is controversial. The objectiv...

journal_title：Neuro-oncology

authors： Corroyer-Dulmont A,Pérès EA,Petit E,Guillamo JS,Varoqueaux N,Roussel S,Toutain J,Divoux D,MacKenzie ET,Delamare J,Ibazizène M,Lecocq M,Jacobs AH,Barré L,Bernaudin M,Valable S

更新日期：2013-01-01 00:00:00

abstract：:A growing body of epidemiologic and tumor genomic research has identified an important role for telomere maintenance in glioma susceptibility, initiation, and prognosis. Telomere length has long been investigated in relation to cancer, but whether longer or shorter telomere length might be associated with glioma risk ...

journal_title：Neuro-oncology

authors： Walsh KM,Wiencke JK,Lachance DH,Wiemels JL,Molinaro AM,Eckel-Passow JE,Jenkins RB,Wrensch MR

更新日期：2015-11-01 00:00:00

abstract：BACKGROUND:Promoter methylation of O(6)-methylguanine-DNA methyltransferase (MGMT) is an important predictive biomarker in glioblastoma. The T variant of the MGMT promoter-enhancer single nucleotide polymorphism (SNP; rs16906252) has been associated with the presence of MGMT promoter methylation in other cancers. We ex...

journal_title：Neuro-oncology

authors： Rapkins RW,Wang F,Nguyen HN,Cloughesy TF,Lai A,Ha W,Nowak AK,Hitchins MP,McDonald KL

更新日期：2015-12-01 00:00:00

abstract：:Radiotherapy is ubiquitous in the treatment of patients with both primary brain tumors as well as disease which is metastatic to the brain. This therapy is not without cost, however, as cognitive decline is frequently associated with cranial radiation, particularly with whole brain radiotherapy (WBRT). The precise mec...

journal_title：Neuro-oncology

authors： Wilke C,Grosshans D,Duman J,Brown P,Li J

更新日期：2018-04-09 00:00:00

abstract：:Diffuse intrinsic pontine glioma (DIPG) has proven to be one of the most challenging of all pediatric cancers. Owing to a historical reticence to obtain tumor tissue for study, and based on an erroneous assumption that the biology of DIPG would mirror that of supratentorial high-grade astrocytomas, innumerable studies...

journal_title：Neuro-oncology

authors： Cohen KJ,Jabado N,Grill J

更新日期：2017-08-01 00:00:00

abstract：:Treatment for newly diagnosed anaplastic oligodendroglial tumors is controversial. Radiotherapy (RT) alone and in combination with chemotherapy (CT) are the most well studied strategies. However, CT alone is often advocated, especially in cases with 1p19q codeletion. We retrospectively identified 1013 adults diagnosed...

journal_title：Neuro-oncology

authors： Lassman AB,Iwamoto FM,Cloughesy TF,Aldape KD,Rivera AL,Eichler AF,Louis DN,Paleologos NA,Fisher BJ,Ashby LS,Cairncross JG,Roldán GB,Wen PY,Ligon KL,Schiff D,Robins HI,Rocque BG,Chamberlain MC,Mason WP,Weaver SA,Gr

更新日期：2011-06-01 00:00:00

abstract：:The vasculature of 24 primary CNS B-cell lymphomas that were not related to acquired immunodeficiency syndrome was systematically studied by electron microscopy. Seven low-grade astrocytic tumors were included for comparison. Classical electron microscopy features of apoptosis were found in lymphoma cells of 21 of 22 ...

journal_title：Neuro-oncology

authors： Molnár PP,O'Neill BP,Scheithauer BW,Groothuis DR

更新日期：1999-04-01 00:00:00

abstract：:With the median survival of 14.6 months following best available standard of care, malignant gliomas (MGs) remain one of the biggest therapeutic challenges of the modern time. Although the last several decades have witnessed tremendous advancement in our understanding of MG and evolution of many successful preclinical...

journal_title：Neuro-oncology

authors： Bentley RT,Ahmed AU,Yanke AB,Cohen-Gadol AA,Dey M

更新日期：2017-03-01 00:00:00

abstract：:Current treatments for brain cancer have, for the most part, equivocal survival benefit. However, clinical trials of new anticancer agents do not adequately assess potential clinical benefits for patient function other than survival and time to tumor progression. We evaluated 56 patients with recurrent brain tumors wh...

journal_title：Neuro-oncology

authors： Meyers CA,Hess KR

更新日期：2003-04-01 00:00:00

abstract：BACKGROUND:The standard of care for newly diagnosed glioblastoma is maximal safe surgical resection, followed by chemoradiation therapy. We assessed carmustine wafer implantation efficacy and safety when used in combination with standard care. METHODS:Included were adult patients with (n = 354, implantation group) and...

journal_title：Neuro-oncology

authors： Pallud J,Audureau E,Noel G,Corns R,Lechapt-Zalcman E,Duntze J,Pavlov V,Guyotat J,Hieu PD,Le Reste PJ,Faillot T,Litre CF,Desse N,Petit A,Emery E,Voirin J,Peltier J,Caire F,Vignes JR,Barat JL,Langlois O,Dezamis E

更新日期：2015-12-01 00:00:00

abstract：:Glioblastoma multiforme (GBM) continues to be a difficult therapeutic challenge. Our study was conducted to determine whether improved survival and tumor control could be achieved with modern delivery of fast neutron radiation using three-dimensional treatment planning. Ten patients were enrolled. Eligibility criteria...

journal_title：Neuro-oncology

authors： Stelzer KJ,Douglas JG,Mankoff DA,Silbergeld DL,Krohn KA,Laramore GE,Spence AM

更新日期：2008-02-01 00:00:00

abstract：BACKGROUND:Targeting immune checkpoint proteins has recently gained substantial attention due to the dramatic success of this strategy in clinical trials for some cancers. Inducible T-cell co-stimulator ligand (ICOSLG) is a member of the B7 family of immune regulatory ligands, expression of which in cancer is implicate...

journal_title：Neuro-oncology

authors： Iwata R,Hyoung Lee J,Hayashi M,Dianzani U,Ofune K,Maruyama M,Oe S,Ito T,Hashiba T,Yoshimura K,Nonaka M,Nakano Y,Norian L,Nakano I,Asai A

更新日期：2020-03-05 00:00:00

abstract：:The majority of meningiomas are probably benign but a number of tumors display considerable histological and/or clinical aggressivity, sometimes with unexpectedly high recurrence rates after radical removal. Understanding the potential behavior of these tumors in individual patients is critical for rational therapeuti...

journal_title：Neuro-oncology

authors： Pérez-Magán E,Rodríguez de Lope A,Ribalta T,Ruano Y,Campos-Martín Y,Pérez-Bautista G,García JF,García-Claver A,Fiaño C,Hernández-Moneo JL,Mollejo M,Meléndez B

更新日期：2010-12-01 00:00:00